ReviewFrontiers in endocrinology2026
Precocious puberty in boys: current insights into etiology, genetic advances, and environmental factors.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Central precocious puberty (CPP) in males results from the premature activation of the hypothalamic-pituitary-gonadal (HPG) axis, clinically diagnosed by a testicular volume >4 mL before the age of 9 years. Over the past two decades, a clear secular trend toward earlier pubertal onset has been reported. Historically, CPP in boys was strongly associated with intracranial lesions, observed in 40-50% of cases. Recent findings: Over the last decade, converging evidence has indicated a markedly lower prevalence of brain lesions in males with CPP, approximately 6-8%. Identified risk factors for intracranial lesions include neurological symptoms, pubertal onset before 8 years, and maternal age at menarche above 11 years. These data support a more selective, risk-based approach to neuroimaging and highlight the need to re-define a new consensus, recently published. Idiopathic CPP represents the majority of cases also in males, with increasing evidence supporting a strong genetic basis. Key mutations include gain-of-function variants in KISS1 and KISS1R, as well as loss-of-function mutations in MKRN3 and DLK1. Additional candidate genes-LIN28B, GABRA1, NPYR, TAC3, and TACR3-have been recently linked to pubertal regulation, although their precise mechanistic roles remain unclear. Beyond genetics, environmental exposures, particularly to endocrine-disrupting chemicals (EDCs), have been implicated in modulating pubertal timing. Conclusion: CPP in boys results from a multifactorial interplay between genetic predisposition and environmental influences. This review summarizes recent evidence regarding the prevalence of brain lesions, emerging genetic discoveries, and the role of endocrine disruptors, to promote a more personalized and precise diagnostic algorithm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.